BDTX-189 manufacturers
- Tuxobertinib
-
- $55.00 / 5mg
-
2025-04-29
- CAS:2414572-47-5
- Min. Order:
- Purity: 99.22%
- Supply Ability: 10g
- BDTX-189; Tuxobertinib
-
- $0.00 / 100MG
-
2025-04-28
- CAS:2414572-47-5
- Min. Order: 10MG
- Purity: 99% HPLC
- Supply Ability: 10000
|
| BDTX-189 Basic information |
Product Name: | BDTX-189 | Synonyms: | BDTX-189;2-Propenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-7-[2-(4-morpholinyl)ethoxy]-6-quinazolinyl]-;Tuxobertinib;Tuxobertinib,inhibit,ErbB-1,EGFR,BDTX 189,BDTX189,mutants,Epidermal growth factor receptor,nude,allosteric,Ba/F3,HER1,oncogene athymic,oral,mice,insertion,Inhibitor;EGFR/HER2 inhibitor BDTX-189;ErbB mutant-specific inhibitor BDTX-189;Tuxobertinib (BDTX-189);Bugatinib | CAS: | 2414572-47-5 | MF: | C29H29ClN6O4 | MW: | 561.03 | EINECS: | | Product Categories: | API;APIs | Mol File: | 2414572-47-5.mol |  |
| BDTX-189 Chemical Properties |
Boiling point | 778.0±60.0 °C(Predicted) | density | 1.349±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO:22.56(Max Conc. mg/mL);40.21(Max Conc. mM) DMF:1.0(Max Conc. mg/mL);1.78(Max Conc. mM) DMF:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.53(Max Conc. mM) | form | A solid | pka | 12.20±0.43(Predicted) | color | Off-white to light yellow |
| BDTX-189 Usage And Synthesis |
Uses | Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity[1]. | in vivo | Tuxobertinib (0-100 mg/kg; p.o.; daily for 15 dyas) shows dose-dependent tumor growth inhibition and regression in in athymic nude mice bearing HER2 S310F Ba/F3 allograft tumors[1]. ?
Tuxobertinib (1-50 mg/kg.p.o.; daily for 15 days) shows dose-dependent tumor growth inhibition and regression in athymic nude mice bearing CUTO-14 PDX tumors that express the EGFR mutation EGFR ASV[1]. | IC 50 | EGFR: 0.2 nM (Kd); HER2: 0.76 nM (Kd); RIPK2: 1.2 nM (Kd); BLK: 13 nM (Kd) | References | [1] Elizabeth Buck, et al. BDTX-189, a Potent and Selective Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations. |
| BDTX-189 Preparation Products And Raw materials |
|